To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the adequacy of access to (a) Creon and (b) other drugs that contain pancreatic enzymes for patients after pancreatic surgery.
Answered on
23 May 2024
We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10,000 gastro-resistant capsules; Creon 25,000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.
Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.